Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Tribute: Edward 'Ned' Lally.

Shenker BJ, Boesze-Battaglia K, Genco CA, Progulske-Fox A.

Mol Oral Microbiol. 2019 Dec;34(6):235-236. doi: 10.1111/omi.12269. Epub 2019 Oct 21. No abstract available.

PMID:
31637856
2.

Internalization of the Active Subunit of the Aggregatibacter actinomycetemcomitans Cytolethal Distending Toxin Is Dependent upon Cellugyrin (Synaptogyrin 2), a Host Cell Non-Neuronal Paralog of the Synaptic Vesicle Protein, Synaptogyrin 1.

Boesze-Battaglia K, Walker LP, Dhingra A, Kandror K, Tang HY, Shenker BJ.

Front Cell Infect Microbiol. 2017 Nov 14;7:469. doi: 10.3389/fcimb.2017.00469. eCollection 2017.

3.

The Cytolethal Distending Toxin Contributes to Microbial Virulence and Disease Pathogenesis by Acting As a Tri-Perditious Toxin.

Scuron MD, Boesze-Battaglia K, Dlakić M, Shenker BJ.

Front Cell Infect Microbiol. 2016 Dec 5;6:168. eCollection 2016. Review.

4.

Variants of Porphyromonas gingivalis lipopolysaccharide alter lipidation of autophagic protein, microtubule-associated protein 1 light chain 3, LC3.

Blasi I, Korostoff J, Dhingra A, Reyes-Reveles J, Shenker BJ, Shahabuddin N, Alexander D, Lally ET, Bragin A, Boesze-Battaglia K.

Mol Oral Microbiol. 2016 Dec;31(6):486-500. doi: 10.1111/omi.12141. Epub 2015 Nov 23.

PMID:
26452236
5.

A Journey of Cytolethal Distending Toxins through Cell Membranes.

Boesze-Battaglia K, Alexander D, Dlakić M, Shenker BJ.

Front Cell Infect Microbiol. 2016 Aug 10;6:81. doi: 10.3389/fcimb.2016.00081. eCollection 2016. Review.

6.

Lymphoid susceptibility to the Aggregatibacter actinomycetemcomitans cytolethal distending toxin is dependent upon baseline levels of the signaling lipid, phosphatidylinositol-3,4,5-triphosphate.

Shenker BJ, Walker LP, Zekavat A, Boesze-Battaglia K.

Mol Oral Microbiol. 2016 Feb;31(1):33-42. doi: 10.1111/omi.12127. Epub 2015 Sep 24.

7.

The toxicity of the Aggregatibacter actinomycetemcomitans cytolethal distending toxin correlates with its phosphatidylinositol-3,4,5-triphosphate phosphatase activity.

Shenker BJ, Boesze-Battaglia K, Scuron MD, Walker LP, Zekavat A, Dlakić M.

Cell Microbiol. 2016 Feb;18(2):223-43. doi: 10.1111/cmi.12497. Epub 2015 Sep 2.

PMID:
26247396
8.

The Aggregatibacter actinomycetemcomitans Cytolethal Distending Toxin Active Subunit CdtB Contains a Cholesterol Recognition Sequence Required for Toxin Binding and Subunit Internalization.

Boesze-Battaglia K, Walker LP, Zekavat A, Dlakić M, Scuron MD, Nygren P, Shenker BJ.

Infect Immun. 2015 Oct;83(10):4042-55. doi: 10.1128/IAI.00788-15. Epub 2015 Jul 27.

9.

Aggregatibacter actinomycetemcomitans cytolethal distending toxin activates the NLRP3 inflammasome in human macrophages, leading to the release of proinflammatory cytokines.

Shenker BJ, Ojcius DM, Walker LP, Zekavat A, Scuron MD, Boesze-Battaglia K.

Infect Immun. 2015 Apr;83(4):1487-96. doi: 10.1128/IAI.03132-14. Epub 2015 Feb 2.

10.

Blockade of the PI-3K signalling pathway by the Aggregatibacter actinomycetemcomitans cytolethal distending toxin induces macrophages to synthesize and secrete pro-inflammatory cytokines.

Shenker BJ, Walker LP, Zekavat A, Dlakić M, Boesze-Battaglia K.

Cell Microbiol. 2014 Sep;16(9):1391-404. doi: 10.1111/cmi.12299. Epub 2014 May 1.

11.

Dental sealants and composite restorations and longitudinal changes in immune function markers in children.

Maserejian NN, Shrader P, Brown OA, Trachtenberg FL, Soncini J, Hauser R, Shenker BJ.

Int J Paediatr Dent. 2014 May;24(3):215-25. doi: 10.1111/ipd.12064. Epub 2013 Sep 4.

12.

PIP3 regulation as promising targeted therapy of mast-cell-mediated diseases.

Shenker BJ, Ali H, Boesze-Battaglia K.

Curr Pharm Des. 2011 Nov;17(34):3815-22. Review.

PMID:
22103853
13.

Inhibition of mast cell degranulation by a chimeric toxin containing a novel phosphatidylinositol-3,4,5-triphosphate phosphatase.

Shenker BJ, Boesze-Battaglia K, Zekavat A, Walker L, Besack D, Ali H.

Mol Immunol. 2010 Nov-Dec;48(1-3):203-10. doi: 10.1016/j.molimm.2010.08.009. Epub 2010 Sep 21.

14.

Cytolethal distending toxin-induced cell cycle arrest of lymphocytes is dependent upon recognition and binding to cholesterol.

Boesze-Battaglia K, Brown A, Walker L, Besack D, Zekavat A, Wrenn S, Krummenacher C, Shenker BJ.

J Biol Chem. 2009 Apr 17;284(16):10650-8. doi: 10.1074/jbc.M809094200. Epub 2009 Feb 23.

15.

Immune function effects of dental amalgam in children: a randomized clinical trial.

Shenker BJ, Maserejian NN, Zhang A, McKinlay S.

J Am Dent Assoc. 2008 Nov;139(11):1496-505.

16.

A novel mode of action for a microbial-derived immunotoxin: the cytolethal distending toxin subunit B exhibits phosphatidylinositol 3,4,5-triphosphate phosphatase activity.

Shenker BJ, Dlakic M, Walker LP, Besack D, Jaffe E, LaBelle E, Boesze-Battaglia K.

J Immunol. 2007 Apr 15;178(8):5099-108.

17.

Cholesterol-rich membrane microdomains mediate cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal-distending toxin.

Boesze-Battaglia K, Besack D, McKay T, Zekavat A, Otis L, Jordan-Sciutto K, Shenker BJ.

Cell Microbiol. 2006 May;8(5):823-36.

19.
20.

Treponema denticola immunoinhibitory protein induces irreversible G1 arrest in activated human lymphocytes.

Lee W, Pankoski L, Zekavat A, Shenker BJ.

Oral Microbiol Immunol. 2004 Jun;19(3):144-9.

PMID:
15107064
21.
22.

Mercury-induced apoptosis in human lymphocytes: caspase activation is linked to redox status.

Shenker BJ, Pankoski L, Zekavat A, Shapiro IM.

Antioxid Redox Signal. 2002 Jun;4(3):379-89.

PMID:
12215206
23.

Maintenance of oxidative phosphorylation protects cells from Actinobacillus actinomycetemcomitans leukotoxin-induced apoptosis.

Yamaguchi N, Kieba IR, Korostoff J, Howard PS, Shenker BJ, Lally ET.

Cell Microbiol. 2001 Dec;3(12):811-23.

PMID:
11736993
24.

Induction of apoptosis in human T cells by Actinobacillus actinomycetemcomitans cytolethal distending toxin is a consequence of G2 arrest of the cell cycle.

Shenker BJ, Hoffmaster RH, Zekavat A, Yamaguchi N, Lally ET, Demuth DR.

J Immunol. 2001 Jul 1;167(1):435-41.

25.
27.
28.
29.
30.

Molecular and biochemical mechanisms of Pasteurella haemolytica leukotoxin-induced cell death.

Wang JF, Kieba IR, Korostoff J, Guo TL, Yamaguchi N, Rozmiarek H, Billings PC, Shenker BJ, Lally ET.

Microb Pathog. 1998 Dec;25(6):317-31.

PMID:
9895270
31.

Mercuric chloride induces apoptosis in human T lymphocytes: evidence of mitochondrial dysfunction.

Guo TL, Miller MA, Shapiro IM, Shenker BJ.

Toxicol Appl Pharmacol. 1998 Dec;153(2):250-7.

PMID:
9878595
32.

Inhibition of poly(ADP-ribose) polymerase rescues human T lymphocytes from methylmercury-induced apoptosis.

Guo TL, Miller MA, Datar S, Shapiro IM, Shenker BJ.

Toxicol Appl Pharmacol. 1998 Oct;152(2):397-405.

PMID:
9853008
33.

Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells.

Korostoff J, Wang JF, Kieba I, Miller M, Shenker BJ, Lally ET.

Infect Immun. 1998 Sep;66(9):4474-83.

34.

Si-Ca-P xerogels and bone morphogenetic protein act synergistically on rat stromal marrow cell differentiation in vitro.

Santos EM, Radin S, Shenker BJ, Shapiro IM, Ducheyne P.

J Biomed Mater Res. 1998 Jul;41(1):87-94.

PMID:
9641628
35.
37.

Modulation of chondrocyte proliferation by ascorbic acid and BMP-2.

Venezian R, Shenker BJ, Datar S, Leboy PS.

J Cell Physiol. 1998 Mar;174(3):331-41.

PMID:
9462695
38.

RTX toxins recognize a beta2 integrin on the surface of human target cells.

Lally ET, Kieba IR, Sato A, Green CL, Rosenbloom J, Korostoff J, Wang JF, Shenker BJ, Ortlepp S, Robinson MK, Billings PC.

J Biol Chem. 1997 Nov 28;272(48):30463-9.

39.

Induction of apoptosis in human T-cells by organomercuric compounds: a flow cytometric analysis.

Shenker BJ, Datar S, Mansfield K, Shapiro IM.

Toxicol Appl Pharmacol. 1997 Apr;143(2):397-406.

PMID:
9144456
40.

Identification and analysis of fipA, a Fusobacterium nucleatum immunosuppressive factor gene.

Demuth DR, Savary R, Golub E, Shenker BJ.

Infect Immun. 1996 Apr;64(4):1335-41.

42.
43.

Bivariate flow karyotyping with air-cooled lasers.

Frey T, Houck DW, Shenker BJ, Hoffman RA.

Cytometry. 1994 Jun 1;16(2):169-74.

44.

Flow cytometric analysis of the cytotoxic effects of Actinobacillus actinomycetemcomitans leukotoxin on human natural killer cells.

Shenker BJ, Vitale LA, Keiba I, Harrison G, Berthold P, Golub E, Lally ET.

J Leukoc Biol. 1994 Feb;55(2):153-60.

PMID:
8301211
45.

Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2.

Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I.

Dev Biol. 1994 Jan;161(1):218-28.

PMID:
8293874
46.

Reconstruction of severe combined immunodeficient mice with lymphocytes from patients with localized juvenile periodontitis.

Shenker BJ, Wannberg S, Vitale L, Kieba I, Lally ET.

J Periodontal Res. 1993 Nov;28(6 Pt 2):487-90. No abstract available.

PMID:
8263717
47.

Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. IV. Alterations in cellular glutathione content.

Shenker BJ, Mayro JS, Rooney C, Vitale L, Shapiro IM.

Immunopharmacol Immunotoxicol. 1993 Mar-Jun;15(2-3):273-90.

PMID:
8349953
48.

Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. III. Alterations in B-cell function and viability.

Shenker BJ, Berthold P, Rooney C, Vitale L, DeBolt K, Shapiro IM.

Immunopharmacol Immunotoxicol. 1993 Jan;15(1):87-112.

PMID:
8450183
49.

Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. II. Alterations in cell viability.

Shenker BJ, Berthold P, Decker S, Mayro J, Rooney C, Vitale L, Shapiro IM.

Immunopharmacol Immunotoxicol. 1992;14(3):555-77.

PMID:
1517534
50.

Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. I. Suppression of T-cell activation.

Shenker BJ, Rooney C, Vitale L, Shapiro IM.

Immunopharmacol Immunotoxicol. 1992;14(3):539-53.

PMID:
1517533

Supplemental Content

Loading ...
Support Center